Join to View Full Profile
601 Crittenden BlvdRochester, NY 14642
Phone+1 585-275-5823
Fax+1 585-273-1051
Dr. Lipe is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Dartmouth-Hitchcock/Mary Hitchcock Memorial HospitalFellowship, Hematology and Medical Oncology, 2008 - 2011- Dartmouth-Hitchcock/Mary Hitchcock Memorial HospitalResidency, Internal Medicine, 2005 - 2008
Albany Medical CollegeClass of 2005
Certifications & Licensure
NH State Medical License 2008 - Present
NY State Medical License 2015 - 2027
KS State Medical License 2011 - 2016
VT State Medical License 2007 - 2008
American Board of Internal Medicine Hematology- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2014, 2016
- CMS Meaningful Use Stage Stage 1 Certification Beacon Oncology 2014 Certified Module, Epic Systems Corporation, 2014, 2016
Clinical Trials
- Denosumab for Smoldering Multiple Myeloma Start of enrollment: 2019 Apr 19
- Selinexor and Backbone Treatments of Multiple Myeloma Patients
Roles: Contact, Principal Investigator
- Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma Start of enrollment: 2023 Aug 21
Roles: Contact, Principal Investigator
Publications & Presentations
PubMed
- Treatment of Multiple Myeloma: ASCO-Ontario Health (Cancer Care Ontario) Living Guideline.Lisa K Hicks, Hans J Messersmith, Samer Al Hadidi, Rahul Banerjee, Benjamin A Derman
Journal of Clinical Oncology. 2026-01-06 - 1 citationsInfections and parameters of humoral immunity with talquetamab in relapsed/refractory multiple myeloma in MonumenTAL-1.Carolina Schinke, Paula Rodriguez-Otero, Niels W C J van de Donk, Brea Lipe, Noa Lavi
Blood Advances. 2025-11-25 - Characterization and Management of Cytokine Release Syndrome From the MonumenTAL-1 Study of Talquetamab in Patients With Relapsed/Refractory Multiple Myeloma.Niels W C J van de Donk, Ajai Chari, Thomas Martin, Amrita Krishnan, Leo Rasche
Cancer Medicine. 2025-10-01
Abstracts/Posters
- Circulating Tumor DNA in the Peripheral Blood As Early Predictor of Clinical Outcome in Relapsed/ Refractory Multiple MyelomaBrea C. Lipe, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- A Phase II Study of Elotuzumab in Combination with Pomalidomide, Bortezomib, and Dexamethasone in Relapsed and Refractory Multiple MyelomaBrea C. Lipe, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Safety and Efficacy of the Combination of Selinexor, Lenalidomide and Dexamethasone (SRd) in Patients with Newly Diagnosed Multiple MyelomaBrea C. Lipe, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Press Mentions
Coping with Two Cancers, Geneva Woman Benefits From Care Close to HomeDecember 8th, 2025- Why — and How — to Exercise When You Have Multiple MyelomaJanuary 3rd, 2023
- Survivorship Plan for Multiple MyelomaDecember 3rd, 2022
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
